Emerging role of nanomedicine in the treatment of neuropathic pain

References

• Jensen TS, Baron R, Haanpää M, et al. A new definition of neuropathic pain. Pain. 2011;152:2204–2205.
   PubMed Web of Science ®Google Scholar
• Gilron I, Baron R, Jensen T, editors. Neuropathic pain: principles of diagnosis and treatment. Mayo Clinic Proceedings; 2015: Elsevier.
   Google Scholar
• McCarberg B, D’Arcy Y, Parsons B, et al. Neuropathic pain: a narrative review of etiology, assessment, diagnosis, and treatment for primary care providers. Curr Med Res Opin. 2017;33:1361–1369.
   PubMed Web of Science ®Google Scholar
• Cohen SP, Mao J. Neuropathic pain: mechanisms and their clinical implications. BMJ. 2014;348:f7656–f7612.
   PubMed Web of Science ®Google Scholar
• Binder A, Baron R. The pharmacological therapy of chronic neuropathic pain. Deutsches Aerzteblatt Int. 2016;113:616–625.
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162–173.
   PubMed Web of Science ®Google Scholar
• Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002.
   PubMed Web of Science ®Google Scholar
• Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain. 2004;5:143–149.
   PubMed Web of Science ®Google Scholar
• Mulla SM, Buckley DN, Moulin DE, et al. Management of chronic neuropathic pain: a protocol for a multiple treatment comparison meta-analysis of randomised controlled trials. BMJ Open. 2014;4:e006112.
   PubMed Web of Science ®Google Scholar
• Tiwari V, Yang F, He S-Q, et al. Activation of peripheral μ-opioid receptors by dermorphin [d-Arg2, Lys4](1–4) amide leads to modality-preferred inhibition of neuropathic pain. Anesthesiology. 2016;124:706–720.
   PubMed Web of Science ®Google Scholar
• Harden N, Cohen M. Unmet needs in the management of neuropathic pain. J Pain Symptom Manage. 2003;25:S12–SS7.
   PubMed Web of Science ®Google Scholar
• Kabu S, Gao Y, Kwon BK, et al. Drug delivery, cell-based therapies, and tissue engineering approaches for spinal cord injury. J Control Release. 2015;219:141–154.
   PubMed Web of Science ®Google Scholar
• Backonja M, Woolf CJ. Future directions in neuropathic pain therapy: closing the translational loop. The Oncologist. 2010;15:24–29.
   PubMed Web of Science ®Google Scholar
• Sprintz M, Tasciotti E, Allegri M, et al. Nanomedicine: ushering in a new era of pain management. Eur J Pain Supple. 2011;5:317–322.
   Google Scholar
• Cusato M, Allegri M, Niebel T, et al. Flip-flop kinetics of ropivacaine during continuous epidural infusion influences its accumulation rate. Eur J Clin Pharmacol. 2011;67:399–406.
   PubMed Web of Science ®Google Scholar
• Breggin LK, Falkner R, Pendergrass J, et al. Addressing the risks of nanomaterials under united states and European union regulatory frameworks for chemicals. Assessing Nanoparticle Risks to Human Health (Second Edition): Elsevier; 2016. p. 179–254.
   Google Scholar
• Provenzale J, Mohs A. Nanotechnology in neurology: current status and future possibilities. US Neurol. 2010;06:12–17.
   Google Scholar
• Boulaiz H, Alvarez PJ, Ramirez A, et al. Nanomedicine: application areas and development prospects. IJMS. 2011;12:3303–3321.
   Google Scholar
• Piktel E, Niemirowicz K, Wątek M, et al. Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy. J Nanobiotechnol. 2016;14:39.
   PubMed Web of Science ®Google Scholar
• Bhise K, Sau S, Alsaab H, et al. Nanomedicine for cancer diagnosis and therapy: advancement, success and structure–activity relationship. Ther Deliv. 2017;8:1003–1018.
   PubMed Web of Science ®Google Scholar
• McCarroll J, Teo J, Boyer C, et al. Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. Front Physiol. 2014;5:2
   PubMedGoogle Scholar
• Solano-Umaña V, Vega-Baudrit JR, González-Paz R. The new field of the nanomedicine. Int J Appl. 2015;5.
   Google Scholar
• Srikanth M, Kessler JA. Nanotechnology – novel therapeutics for CNS disorders. Nat Rev Neurol. 2012;8:307–318.
   PubMed Web of Science ®Google Scholar
• Pelaz B, Alexiou C, Alvarez-Puebla RA, et al. Diverse applications of nanomedicine. ACS Publications; 2017.
   Google Scholar
• Ledet G, Mandal TK. Nanomedicine: emerging therapeutics for the 21st century. US Pharm. 2012;37:7–11.
   Google Scholar
• Bamrungsap S, Zhao Z, Chen T, et al. Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system. Nanomedicine (Lond). 2012;7:1253–1271.
   PubMed Web of Science ®Google Scholar
• Kessler TL. Treatments for neuropathic pain. Lung Cancer. 2018;15:05.
   Google Scholar
• Clark AK, Yip PK, Grist J, et al. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci. 2007;104:10655–10660.
   PubMed Web of Science ®Google Scholar
• Zhuang Z-Y, Gerner P, Woolf CJ, et al. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain. 2005;114:149–159.
   PubMed Web of Science ®Google Scholar
• Hancock JF, Magee AI, Childs JE, et al. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell. 1989;57:1167–1177.
   PubMed Web of Science ®Google Scholar
• Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002;42:1228–1236.
   PubMed Web of Science ®Google Scholar
• Caraglia M, Luongo L, Salzano G, et al. Stealth liposomes encapsulating zoledronic acid: a new opportunity to treat neuropathic pain. Mol Pharmaceutics. 2013;10:1111–1118.
   PubMed Web of Science ®Google Scholar
• Lalani J, Patil S, Kolate A, et al. Protein-functionalized PLGA nanoparticles of lamotrigine for neuropathic pain management. AAPS PharmSciTech. 2015;16:413–427.
   PubMed Web of Science ®Google Scholar
• Marazziti D, Rotondo A, Ambrogi F, et al. Analgesia by nefopam: does it act through serotonin? Drugs under Exp Clin Res. 1990;17:259–261.
   Google Scholar
• Fuller RW, Snoddy HD. Evaluation of nefopam as a monoamine uptake inhibitor in vivo in mice. Neuropharmacology. 1993;32:995–999.
   PubMed Web of Science ®Google Scholar
• Esposito E, Romandini S, Merlo-Pich E, et al. Evidence of the involvement of dopamine in the analgesic effect of nefopam. Eur J Pharmacol. 1986;128:157–164.
   PubMed Web of Science ®Google Scholar
• Sukhbir S, Yashpal S, Sandeep A. Development and statistical optimization of nefopam hydrochloride loaded nanospheres for neuropathic pain using Box–Behnken design. Saudi Pharmaceutical J. 2016;24:588–599.
   PubMed Web of Science ®Google Scholar
• Agarwal N, Pacher P, Tegeder I, et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci. 2007;10:870.
   PubMed Web of Science ®Google Scholar
• Bridges D, Ahmad K, Rice AS. The synthetic cannabinoid WIN55, 212‐2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol. 2001;133:586–594.
   PubMed Web of Science ®Google Scholar
• Sain NM, Liang A, Kane SA, et al. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain. Neuropharmacology. 2009;57:235–241.
   PubMed Web of Science ®Google Scholar
• Eissens A, Van Drooge D, Hinrichs W, et al. Stabilized natural cannabinoid formulation. Google Patents; 2003.
   Google Scholar
• Gardin A, Kucher K, Kiese B, et al. CRA13, a Novel Cannabinoid agonist: first in human pharmacokinetics and safety. Drug Metab Dispos. 2009;37:827–833.
   PubMed Web of Science ®Google Scholar
• Martín-Banderas L, Álvarez-Fuentes J, Durán-Lobato M, et al. Cannabinoid derivate-loaded PLGA nanocarriers for oral administration: formulation, characterization, and cytotoxicity studies. Int J Nanomed. 2012;7:5793.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang S, Zhang M, et al. Nanocarriers for oral drug delivery. J Drug Target. 2013;21:515–527.
   PubMed Web of Science ®Google Scholar
• Durán-Lobato M, Martín-Banderas L, Gonçalves LM, et al. Comparative study of chitosan-and PEG-coated lipid and PLGA nanoparticles as oral delivery systems for cannabinoids. J Nanoparticle Res. 2015;17:61.
   Web of Science ®Google Scholar
• Clapper JR, Moreno-Sanz G, Russo R, et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci. 2010;13:1265–1270.
   PubMed Web of Science ®Google Scholar
• Yu XH, Cao CQ, Martino G, et al. A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain. PAIN^®. 2010;151:337–344.
   PubMed Web of Science ®Google Scholar
• Linsell O, Brownjohn PW, Nehoff H, et al. Effect of styrene maleic acid WIN55,212-2 micelles on neuropathic pain in a rat model. J Drug Target. 2015;23:353–359.
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Bronich TK, Vetro JA, et al. Polymer micelles as drug carriers. Nanoparticulates Drug Carr. 2006;57–93.
   Google Scholar
• Xie W, Strong JA, Zhang J-M. Early blockade of injured primary sensory afferents reduces glial cell activation in two rat neuropathic pain models. Neurosci. 2009;160:847–857.
   PubMed Web of Science ®Google Scholar
• Suter MR, Papaloïzos M, Berde CB, et al. Development of neuropathic pain in the rat spared nerve injury model is not prevented by a peripheral nerve block. Anesthesiology. 2003;99:1402–1408.
   PubMed Web of Science ®Google Scholar
• Nejati-Koshki K, Mortazavi Y, Pilehvar-Soltanahmadi Y, et al. An update on application of nanotechnology and stem cells in spinal cord injury regeneration. Biomed Pharmacother. 2017;90:85–92.
   PubMed Web of Science ®Google Scholar
• Shankarappa SA, Kohane DS. Controlled-release systems in neuropathic pain. Pain Manag. 2013;3:91–93.
   PubMedGoogle Scholar
• Santamaria CM, Woodruff A, Yang R, et al. Drug delivery systems for prolonged duration local anesthesia. Mater. Today. 2017;20:22–31.
   Web of Science ®Google Scholar
• de Paula E, Cereda CM, Fraceto LF, et al. Micro and nanosystems for delivering local anesthetics. Expert Opin Drug Deliv. 2012;9:1505–1524.
   PubMed Web of Science ®Google Scholar
• McAlvin JB, Reznor G, Shankarappa SA, et al. Local toxicity from local anesthetic polymeric microparticles. Anesth Analg. 2013;116:794
   PubMed Web of Science ®Google Scholar
• Viscusi ER, Sinatra R, Onel E, et al. The safety of liposome bupivacaine, a novel local analgesic formulation. Clin J Pain. 2014;30:102–110.
   PubMed Web of Science ®Google Scholar
• Dudala TB, Yalavarthi PR, Vadlamudi HC, et al. A perspective overview on lipospheres as lipid carrier systems. Int J Pharma Investig. 2014;4:149.
   PubMedGoogle Scholar
• Loftsson T, Jarho P, Masson M, et al. Cyclodextrins in drug delivery. Expert Opin Drug Deliv. 2005;2:335–351.
   PubMed Web of Science ®Google Scholar
• Ulery BD, Nair LS, Laurencin CT. Biomedical applications of biodegradable polymers. J Polym Sci B Polym Phys. 2011;49:832–864.
   PubMed Web of Science ®Google Scholar
• Hoare TR, Kohane DS. Hydrogels in drug delivery: progress and challenges. Polymer. 2008;49:1993–2007.
   Web of Science ®Google Scholar
• Timko BP, Dvir T, Kohane DS. Remotely triggerable drug delivery systems. Adv Mater. 2010;22:4925–4943.
   PubMed Web of Science ®Google Scholar
• Garcia X, Escribano E, Domenech J, et al. In vitro characterization and in vivo analgesic and anti-allodynic activity of PLGA-bupivacaine nanoparticles. J Nanopart Res. 2011;13:2213–2223.
   Web of Science ®Google Scholar
• Hua S, Cabot PJ. Targeted nanoparticles that mimic immune cells in pain control inducing analgesic and anti-inflammatory actions: a potential novel treatment of acute and chronic pain conditions. Pain Physician. 2013;16:E199–E216.
   PubMed Web of Science ®Google Scholar
• Gilron I, Jensen TS, Dickenson AH. Combination pharmacotherapy for management of chronic pain: from bench to bedside. Lancet Neurol. 2013;12:1084–1095.
   PubMed Web of Science ®Google Scholar
• Chakravarthy KV, Boehm FJ, Christo PJ. Nanotechnology: a promising new paradigm for the control of pain. Pain Med. 2018;19:232–243.
   PubMed Web of Science ®Google Scholar
• George A, Marziniak M, Schäfers M, et al. Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-α, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain. 2000;88:267–275.
   PubMed Web of Science ®Google Scholar
• Mao J, Chen LL. Systemic lidocaine for neuropathic pain relief. Pain. 2000;87:7–17.
   PubMed Web of Science ®Google Scholar
• Song T, Gu K, Wang W, et al. Prolonged suppression of neuropathic pain by sequential delivery of lidocaine and thalidomide drugs using PEGylated graphene oxide. J Pharmaceutical Sci. 2015;104:3851–3860.
   PubMed Web of Science ®Google Scholar
• Matsushita Y, Ueda H. Curcumin blocks chronic morphine analgesic tolerance and brain-derived neurotrophic factor upregulation. Neuroreport. 2009;20:63–68.
   PubMed Web of Science ®Google Scholar
• Anand P, Kunnumakkara AB, Newman RA, et al. Bioavailability of curcumin: problems and promises. Mol Pharmaceutics. 2007;4:807–818.
   PubMed Web of Science ®Google Scholar
• Shen H, Hu X, Szymusiak M, et al. Orally administered nanocurcumin to attenuate morphine tolerance: comparison between negatively charged PLGA and partially and fully PEGylated nanoparticles. 2013;10:4546–4551.
   Google Scholar
• Wilson B, Lavanya Y, Priyadarshini S, et al. Albumin nanoparticles for the delivery of gabapentin: preparation, characterization and pharmacodynamic studies. Int J Pharmaceu. 2014;473:73–79.
   PubMed Web of Science ®Google Scholar
• Senthilnathan B, Maheswaran A, Gopalasatheeskumar K, et al. Formulation and evaluation of pregabalin loaded eudragit S100 nanoparticles. Int J Eng Tech Sci. 2016;6:64–70.
   Google Scholar
• São Pedro A, Fernandes R, Flora Villarreal C, et al. Opioid-based micro and nanoparticulate formulations: alternative approach on pain management. J Microencapsulation. 2016;33:18–29.
   PubMed Web of Science ®Google Scholar
• Martín-Banderas L, Munoz-Rubio I, Álvarez-Fuentes J, et al. Engineering of Δ9-tetrahydrocannabinol delivery systems based on surface modified-PLGA nanoplatforms. Colloids Surf B Biointerfaces. 2014;123:114–122.
   PubMed Web of Science ®Google Scholar
• Lalani J, Rathi M, Lalan M, et al. Protein functionalized tramadol-loaded PLGA nanoparticles: preparation, optimization, stability and pharmacodynamic studies. Drug Develop Ind Pharm. 2013;39:854–864.
   PubMed Web of Science ®Google Scholar
• Hoekman JD, Srivastava P, Ho RJ. Aerosol‐stable peptide‐coated liposome nanoparticles: a proof‐of‐concept study with opioid fentanyl in enhancing analgesic effects and reducing plasma drug exposure. J Pharmaceutical Sci. 2014;103:2231–2239.
   PubMed Web of Science ®Google Scholar
• Tosi G, Costantino L, Rivasi F, et al. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J Control Release. 2007;122:1–9.
   PubMed Web of Science ®Google Scholar
• Anand P, O’Neil A, Lin E, et al. Tailored delivery of analgesic ziconotide across a blood brain barrier model using viral nanocontainers. Sci Rep. 2015;5:12497.
   PubMed Web of Science ®Google Scholar
• Baskaran M, Baskaran P, Arulsamy N, et al. Preparation and evaluation of PLGA-coated capsaicin magnetic nanoparticles. Pharm Res. 2017;34:1255–1263.
   PubMed Web of Science ®Google Scholar
• Astruc‐Diaz F, Mcdaniel SW, et al. In vivo efficacy of enabling formulations based on hydroxypropyl‐β‐cyclodextrins, micellar preparation, and liposomes for the lipophilic cannabinoid CB2 agonist, MDA7. J Pharmaceu Sci. 2013;102:352–364.
   PubMed Web of Science ®Google Scholar
• Liu Q, Jin L, Mahon BH, et al. A novel treatment of neuroinflammation against low back pain by soluble fullerol nanoparticles. Spine. 2013;38:1443.
   PubMed Web of Science ®Google Scholar
• Franchi S, Castelli M, Amodeo G, et al. Adult stem cell as new advanced therapy for experimental neuropathic pain treatment. BioMed Res Int. 2014;2014:1.
   Google Scholar
• Nandoe Tewarie RS, Hurtado A, Bartels RH, et al. Stem cell-based therapies for spinal cord injury. J Spinal Cord Med. 2009;32:105–114.
   PubMed Web of Science ®Google Scholar
• Bossio C, Mastrangelo R, Morini R, et al. A simple method to generate adipose stem cell-derived neurons for screening purposes. J Mol Neurosci. 2013;51:274–281.
   PubMed Web of Science ®Google Scholar
• Franchi S, Valsecchi AE, Borsani E, et al. Intravenous neural stem cells abolish nociceptive hypersensitivity and trigger nerve regeneration in experimental neuropathy. PAIN^®. 2012;153:850–861.
   PubMed Web of Science ®Google Scholar
• Luo Y, Zou Y, Yang L, et al. Transplantation of NSCs with OECs alleviates neuropathic pain associated with NGF downregulation in rats following spinal cord injury. Neurosci Lett. 2013;549:103–108.
   PubMed Web of Science ®Google Scholar
• Klass M, Gavrikov V, Drury D, et al. Intravenous mononuclear marrow cells reverse neuropathic pain from experimental mononeuropathy. Anesth Analg. 2007;104:944–948.
   PubMed Web of Science ®Google Scholar
• Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–147.
   PubMed Web of Science ®Google Scholar
• Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mboc. 2002;13:4279–4295.
   Google Scholar
• Salazar DL, Uchida N, Hamers FP, et al. Human neural stem cells differentiate and promote locomotor recovery in an early chronic spinal cord injury NOD-scid mouse model. PLoS One. 2010;5:e12272.
   PubMed Web of Science ®Google Scholar
• Sacerdote P, Niada S, Franchi S, et al. Systemic administration of human adipose-derived stem cells reverts nociceptive hypersensitivity in an experimental model of neuropathy. Stem Cells Develop. 2013;22:1252–1263.
   PubMed Web of Science ®Google Scholar
• De Girolamo L, Sartori M, Arrigoni E, et al. Human adipose-derived stem cells as future tools in tissue regeneration: osteogenic differentiation and cell-scaffold interaction. Int J Artif Organs. 2008;31:467–479.
   PubMed Web of Science ®Google Scholar
• Choi JI, Cho HT, Jee MK, et al. Core-shell nanoparticle controlled hATSCs neurogenesis for neuropathic pain therapy. Biomaterials. 2013;34:4956–4970.
   PubMed Web of Science ®Google Scholar
• Sloane E, Langer S, Jekich J, et al. Resolution of neuropathic pain by intrathecal (IT) gene therapy to induce interleukin-10 (IL-10): initial exploration of mechanisms. Sydney, Australia: International Association for the Study of Pain; 2005.
   Google Scholar
• Goins WF, Cohen JB, Glorioso JC. Gene therapy for the treatment of chronic peripheral nervous system pain. Neurobiol Dis. 2012;48:255–270.
   PubMed Web of Science ®Google Scholar
• Shi L, Tang G, Gao S, et al. Repeated intrathecal administration of plasmid DNA complexed with polyethylene glycol-grafted polyethylenimine led to prolonged transgene expression in the spinal cord. Gene Ther. 2003;10:1179.
   PubMed Web of Science ®Google Scholar
• Belyanskaya L, Weigel S, Hirsch C, et al. Effects of carbon nanotubes on primary neurons and glial cells. Neurotoxicology. 2009;30:702–711.
   PubMed Web of Science ®Google Scholar
• Chen KH, Wu CH, Tseng CC, et al. Intrathecal coelectrotransfer of a tetracycline‐inducible, three‐plasmid‐based system to achieve tightly regulated antinociceptive gene therapy for mononeuropathic rats. J Gene Med. 2008;10:208–216.
   PubMed Web of Science ®Google Scholar
• Chuang Y-C, Chou A-K, Wu P-C, et al. Gene therapy for bladder pain with gene gun particle encoding pro-opiomelanocortin cDNA. J Urol. 2003;170:2044–2048.
   PubMed Web of Science ®Google Scholar
• Yamashita M, Yamauchi K, Suzuki M, et al. Transfection of rat cells with proopiomeranocortin gene, precursor of endogenous endorphin, using radial shock waves suppresses inflammatory pain. Spine. 2009;34:2270–2277.
   PubMed Web of Science ®Google Scholar
• Lin C-R, Chen K-H, Yang C-H, et al. Sonoporation-mediated gene transfer into adult rat dorsal root ganglion cells. J Biomed Sci. 2010;17:44.
   PubMed Web of Science ®Google Scholar
• Hao S, Mata M, Glorioso J, et al. Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Ther. 2007;14:1010.
   PubMed Web of Science ®Google Scholar
• Gerard E, Spengler RN, Bonoiu AC, et al. Chronic constriction injury-induced nociception is relieved by nanomedicine-mediated decrease of rat hippocampal tumor necrosis factor. Pain. 2015;156:1320–1333.
   PubMed Web of Science ®Google Scholar
• Milligan ED, Sloane EM, Langer SJ, et al. Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10. Mol Pain. 2005;1:9.
   PubMed Web of Science ®Google Scholar
• Milligan ED, Langer SJ, Sloane EM, et al. Controlling pathological pain by adenovirally driven spinal production of the anti‐inflammatory cytokine, interleukin‐10. Eur J Neurosci. 2005;21:2136–2148.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Peng X, Hao S, et al. HSV-mediated transfer of interleukin-10 reduces inflammatory pain through modulation of membrane tumor necrosis factor α in spinal cord microglia. Gene Ther. 2008;15:183.
   PubMed Web of Science ®Google Scholar
• Soderquist RG, Sloane EM, Loram LC, et al. Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administration. Pharm Res. 2010;27:841–854.
   PubMed Web of Science ®Google Scholar
• Andreu V, Arruebo M. Current progress and challenges of nanoparticle-based therapeutics in pain management. J Control Release. 2018;269:189–213.
   PubMed Web of Science ®Google Scholar
• Shcharbina N, Shcharbin D, Bryszewska M. Nanomaterials in Stroke treatment: perspectives. Stroke. 2013;44:2351–2355.
   PubMed Web of Science ®Google Scholar
• Sarmah D, Saraf J, Kaur H, et al. Stroke management: an emerging role of nanotechnology. Micromachines. 2017;8:262.
   PubMed Web of Science ®Google Scholar
• Oberdörster G, Maynard A, Donaldson K, et al. Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Particle Fibre Toxicol. 2005;2:8.
   PubMed Web of Science ®Google Scholar
• Geiser M, Rothen-Rutishauser B, Kapp N, et al. Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells. Environ Health Perspect. 2005;113:1555.
   PubMed Web of Science ®Google Scholar
• Huk A, Izak-Nau E, El Yamani N, et al. Impact of nanosilver on various DNA lesions and HPRT gene mutations–effects of charge and surface coating. Particle Fibre Toxicol. 2015;12:25.
   PubMed Web of Science ®Google Scholar
• Xu L, Liang H-W, Yang Y, et al. Stability and reactivity: positive and negative aspects for nanoparticle processing. Chem Rev. 2018;118:3209–3250.
   PubMed Web of Science ®Google Scholar
• Sanhai WR, Sakamoto JH, Canady R, et al. Seven challenges for nanomedicine. Nature Nanotech. 2008;3:242.
   PubMed Web of Science ®Google Scholar
• Wicki A, Witzigmann D, Balasubramanian V, et al. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015;200:138–157.
   PubMed Web of Science ®Google Scholar
• Lewinski N, Colvin V, Drezek R. Cytotoxicity of nanoparticles. Small. 2008;4:26–49.
   PubMed Web of Science ®Google Scholar
• Arnstein PM. The future of topical analgesics. Postgrad Med. 2013;125:34–41.
   PubMedGoogle Scholar